Genentech in rare deal to buy preclinical tumour metabolism programme from Forma
07 July 2011
Nancy Faigen
Please Login to read the full article.
07 July 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Forma nets $65M upfront from Boehringer to drug "undruggable" cancer targets
- Forma strikes discovery deal with Janssen in cancer metabolism, worth up to $700M
- "Welcome home": Stromedix buy brings fibrosis drug back to Biogen
- Rib-X inks potentially lucrative deal with Sanofi for new class of antibiotics
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
